Bob More is a member of the board of directors at Vir. He has more than 22 years of life sciences investing experience and currently serves as managing director at Alta Partners.
Bob was a Senior Advisor for the Bill and Melinda Gates Foundation and remains an advisor to the foundation. Prior to that, Bob spent 5 years as a General Partner at Frazier Healthcare Ventures and 13 years at Domain Associates. Bob managed successful investments in and served on the boards of Achaogen (NASDAQ: AKAO), Cartiva (acquired by Wright Medical), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Glaukos Corporation (NYSE: GKOS), IntraLase (acquired by Advanced Medical Optics), Neothetics (NASDAQ: NEOT), NovaCardia (acquired by Merck), Oceana Therapeutics (acquired by Salix Pharmaceuticals) and Proxima Therapeutics (acquired by Cytyc Corporation). Bob was also an investor in Clovis Oncology (NASDAQ: CLVS), Encoded Genomics and Zeltiq Aesthetics (acquired by Allergan).
Bob currently manages investments in and serves on the board of Affinivax, Carticept, eGenesis, Qihan Biopharmaceuticals, Sienna Biopharmaceuticals (NASDAQ: SNNA) and Sirenas MD. He was a founding board member of the Kauffman Fellows Program and is on the board of BIO (Biotechnology Innovation Organization).
He received his B.A. from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.